IASLC GENERAL DISCLAIMER

Multidisciplinary EURACAN/IASLC Proposal for Revision of the Histologic Classification of Malignant Pleural Mesothelioma 

Improving Molecular Testing in Lung Cancer: What We Learned From the IASLC Global Survey 

IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens Following Neoadjuvant Therapies

PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee

Tumor Mutation Burden: Evolution of a Controversial Biomarker From the Pathologist’s Perspective

PD-L1 in Cytology Specimens

Global Survey for Pathologists on PD-L1 Testing: Moving Toward Standardization

Special Session to Honor Dr. Adi Gazdar

Ki-67 in Pulmonary Neuroendocrine Tumors: Where Do We Stand?

The IASLC Pathology Committee Recommendations for the Use of Diagnostic Immunohistochemistry in Lung Cancer

Diagnostic Oncology: Reports from the IASLC Pathology Committee